To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.
Bone Marrow
Hematopoietic-Stem-Cell Transplantation
Among Oldest Forms of Cancer Immunotherapy
Targeted therapies that mobilize the body’s
immune system to attack cancer cells continue
to emerge as promising weapons in the arsenal
of cancer treatment options. But the idea
behind cancer immunotherapy is not a new
one. More commonly known as bone-marrow
transplantation (BMT), hematopoietic-stem-cell
transplantation (HSCT) has been performed
in the United States for more than 40 years
to support patients undergoing treatment for
cancers such as acute myeloid leukemia (AML),
multiple myeloma or lymphoma.
This image illustrates in detail the
characteristic morphologic features
of the myeloid response following
G-CSF stem cell mobilization.
Photo: American Society of Hematology
STORY HIGHLIGHTS
Hematopoietic-stem-cell transplantation
has been performed in the United States
for more than 40 years to support patients
undergoing treatment for cancers such
as acute myeloid leukemia, multiple
myeloma or lymphoma.
While using allogeneic stem cells carries
major risks of infection and graft-
versus-host disease, newer strategies
have led to fewer complications and
improved outcomes.
UCLAHEALTH.ORG “Few immune therapies have the track record
and demonstrated effi cacy that we observe with
HSCT,” says Gary Schiller, MD, director of the
Hematologic Malignancies/Stem Cell Transplant
Unit at UCLA. “It is the most common immune
therapy done in the world for cancer and is
the immune therapy for which there is the
greatest experience.”
In fact, more than 60,000 HSCTs are performed
internationally each year, according to
Dr. Schiller. Approximately half of transplanted
hematopoietic stem cells (those capable of
reconstituting bone marrow and blood) are
autologous, in which the recipient acts as his or
her own donor. The other half are allogeneic,
in which stem cells are donated from related
(usually a sibling with closely matched human
leukocyte antigens) or unrelated adults or from
the umbilical-cord blood of a newborn. Both
procedures are done to replace bone marrow
damaged or destroyed by chemo or radiation
therapies delivered to treat malignancies with
healthy bone-marrow stem cells. Allogeneic
HSCTs, however, also serve another purpose.
“Allogeneic HSCTs deliver an immunoreactive
organ, which is more likely to favorably impact
1-800-UCLA-888 (1-800-825-2888)
the disease,” Dr. Schiller explains. “When using
allogeneic stem cells, the chemo and radiation
therapies do not necessarily need to completely
kill every last malignant cell because some of
the heavy lift ing will be done by the donor’s
immune system.”
The procedure carries major risks. Infection
and graft-versus-host disease, an inflammatory
condition in which the immune cells of
the donor attack the recipient’s tissues, are
major complications of allogeneic HSCT.
Newer strategies, however, have led to fewer
complications and improved outcomes.
“Few ‘immune therapies’ have the
track record and demonstrated
effi cacy that we observe with
HSCT. It is the most common
immune therapy done in the
world for cancer.”
“We have become better at identifying and
matching potential donors; we have begun to
reduce the chemo and radiation therapy we use to
treat malignancies because we are more skilled in
harnessing the immune effect of donor cells; and
we have more effective antibiotics that we use to
prevent infections,” Dr. Schiller says.
These developments have enabled physicians to
expand allogeneic HSCTs to broader populations
of patients for whom the risks of transplantation
might have previously been too great. For
example, “mini-transplant” procedures have been